Seralutinib's Phase 3 PAH Trial Demonstrates Improvement Despite Missing Key Threshold The phase 3 PROSERA study found that seralutinib demonstrates clear improvement in patients with PAH, according to a press release.

In the #PROSERA phase 3 study, #Seralutinib demonstrated a placebo-adjusted increase of 13.3 m in the 6-minute walk distance, with more pronounced improvements observed in high-risk subgroups.

Learn more: https://bit.ly/4lb32Qd

#RareDisease #PAH #PulmonaryArterialHypertension #PAH